Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The study will assess pharmacokinetic (PK) comparability between different formulations of AZD7442, which is a combination of two individual monoclonal antibodies (mAbs), AZD8895 and AZD1061.
Epistemonikos ID: e7592047e939ce8286a1d8f4d9fea7ff74ef48f3
First added on: Dec 23, 2021